{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T23:09:43Z","timestamp":1719875383803},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,21]]},"DOI":"10.7759\/cureus.45697","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T15:34:05Z","timestamp":1695310445000},"source":"Crossref","is-referenced-by-count":1,"title":["Dasatinib-Associated Acneiform Eruption Successfully Treated With Sarecycline in a Patient With Chronic Myeloid Leukemia"],"prefix":"10.7759","author":[{"given":"Dina","family":"Poplausky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jade N","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle P","family":"Dubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.s3425","article-title":"Dasatinib in chronic myeloid leukemia: a review","volume":"5","author":"Aguilera DG","year":"2009","unstructured":"Aguilera DG, Tsimberidou AM. Dasatinib in chronic myeloid leukemia: a review. Ther Clin Risk Manag. 2009, 5:281-9. 10.2147\/tcrm.s3425","journal-title":"Ther Clin Risk Manag"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25429","article-title":"Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis","volume":"62","author":"Belum VR","year":"2015","unstructured":"Belum VR, Washington C, Pratilas CA, Sibaud V, Boralevi F, Lacouture ME. Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis. Pediatr Blood Cancer. 2015, 62:798-806. 10.1002\/pbc.25429","journal-title":"Pediatr Blood Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14185","article-title":"Acneiform eruptions caused by various second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia","volume":"174","author":"Jung YS","year":"2016","unstructured":"Jung YS, Kim M, Lee JH, Kim DW, Park HJ. Acneiform eruptions caused by various second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Dermatol. 2016, 174:456-8. 10.1111\/bjd.14185","journal-title":"Br J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.15704","article-title":"Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: a review","volume":"22","author":"Yuan C","year":"2023","unstructured":"Yuan C, Wang B. Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: a review. J Cosmet Dermatol. 2023, 22:2150-7. 10.1111\/jocd.15704","journal-title":"J Cosmet Dermatol"},{"key":"ref5","article-title":"Safety and tolerability of sarecycline for the treatment of acne vulgaris: results from a Phase III, multicenter, open-label study and a Phase I phototoxicity study","volume":"12","author":"Pariser DM","year":"2019","unstructured":"Pariser DM, Green LJ, Lain EL, Schmitz C, Chinigo AS, McNamee B, Berk DR. Safety and tolerability of sarecycline for the treatment of acne vulgaris: results from a Phase III, multicenter, open-label study and a Phase I phototoxicity study. J Clin Aesthet Dermatol. 2019, 12:E53-62.","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200203060-00003","article-title":"Pustular skin disorders: diagnosis and treatment","volume":"3","author":"Mengesha YM","year":"2002","unstructured":"Mengesha YM, Bennett ML. Pustular skin disorders: diagnosis and treatment. Am J Clin Dermatol. 2002, 3:389-400. 10.2165\/00128071-200203060-00003","journal-title":"Am J Clin Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.005","article-title":"Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines\u2606","volume":"32","author":"Lacouture ME","year":"2021","unstructured":"Lacouture ME, Sibaud V, Gerber PA, et al.. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines\u2606. Ann Oncol. 2021, 32:157-70. 10.1016\/j.annonc.2020.11.005","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25090","article-title":"Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life","volume":"116","author":"Joshi SS","year":"2010","unstructured":"Joshi SS, Ortiz S, Witherspoon JN, et al.. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer. 2010, 116:3916-23. 10.1002\/cncr.25090","journal-title":"Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07257-2","article-title":"Acneiform eruptions with combination targeted cancer therapy in colorectal cancer patients","volume":"30","author":"Ibraheim MK","year":"2022","unstructured":"Ibraheim MK, Lo J, Gupta R, Parseghian C, Patel AB. Acneiform eruptions with combination targeted cancer therapy in colorectal cancer patients. Support Care Cancer. 2022, 30:8051-8. 10.1007\/s00520-022-07257-2","journal-title":"Support Care Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-023-01428-9","article-title":"Repurposing sarecycline for osteoinductive therapies: an in vitro and ex vivo assessment","volume":"41","author":"Martin V","year":"2023","unstructured":"Martin V, Grenho L, Fernandes MH, Gomes PS. Repurposing sarecycline for osteoinductive therapies: an in vitro and ex vivo assessment. J Bone Miner Metab. 2023, 41:431-42. 10.1007\/s00774-023-01428-9","journal-title":"J Bone Miner Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63574-2","article-title":"Hedgehog signaling regulates sebaceous gland development","volume":"163","author":"Allen M","year":"2003","unstructured":"Allen M, Grachtchouk M, Sheng H, et al.. Hedgehog signaling regulates sebaceous gland development. Am J Pathol. 2003, 163:2173-8. 10.1016\/S0002-9440(10)63574-2","journal-title":"Am J Pathol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/183687-dasatinib-associated-acneiform-eruption-successfully-treated-with-sarecycline-in-a-patient-with-chronic-myeloid-leukemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:08:17Z","timestamp":1707509297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/183687-dasatinib-associated-acneiform-eruption-successfully-treated-with-sarecycline-in-a-patient-with-chronic-myeloid-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.45697","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,21]]}}}